Cyclo Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

false 0000922247 0000922247 2024-09-09 2024-09-09 0000922247 ctdh:CommonStockParValue0001PerShareCustomMember 2024-09-09 2024-09-09 0000922247 ctdh:WarrantsToPurchaseCommonStockCustomMember 2024-09-09 2024-09-09

 

 

 

 

Date of Report (Date of earliest event reported)

 

(Exact name of registrant as specified in its charter)

 

 

 

Registrant’s telephone number, including area code

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 

 

 

On September 9, 2024, Cyclo Therapeutics, Inc., a Nevada corporation (the “Company”), entered into a Third Amended and Restated Note Purchase Agreement (the “Agreement”) with Rafael Holdings, Inc., a Delaware corporation (“Rafael”), pursuant to which the Company issued and sold a convertible promissory note in the principal amount of $3,000,000.00 (the “Note”) to Rafael. The Agreement amends and restates the Second Amended and Restated Note Purchase Agreement (the “August Agreement”), dated August 21, 2024, by and between the Company and Rafael, pursuant to which the Company issued and sold another convertible promissory note in the principal amount of $3,000,000.00 (the “August Note”) to Rafael. The August Agreement had amended and restated the Amended and Restated Note Purchase Agreement (the “July Agreement”), dated July 16, 2024, by and between the Company and Rafael, pursuant to which the Company issued and sold a convertible promissory note in the principal amount of $2,000,000.00 (the “July Note”) to Rafael. The July Agreement had amended and restated the Note Purchase Agreement, dated June 11, 2024, by and between the Company and Rafael, pursuant to which the Company issued and sold an initial convertible promissory note in the principal amount of $2,000,000.00 (the “June Note”) to Rafael. The Note matures on December 21, 2024 and bears interest at a rate of 5% per annum, payable upon maturity. The Note may be prepaid by the Company in full at any time. The principal amount of the Note is convertible into shares of the Company’s outstanding common stock, par value $0.0001 per share (the “Common Stock”), prior to the repayment of the Note, at the option of Rafael; automatically if the Company enters into a Qualified Financing (as defined) and at the option of Rafael if a Sale Transaction (as defined) occurs prior to repayment of the Note, all at the price and on the terms and conditions set forth in the Note. Upon the occurrence of an Event of Default (as defined) under the Note, including the failure of the Company to pay the principal or interest under either the Note, the June Note, the July Note or the August Note, when due, the obligations of the Company under the Note, the June Note, the July Note and the August Note may be accelerated. The Company intends to use the proceeds of the Note for working capital and general corporate purposes.

 

Rafael is the holder of approximately 31.4% of the Common Stock, and the Company has entered into an Agreement and Plan of Merger, dated August 21, 2024 (the “Merger Agreement”), with Rafael and the other parties thereto pursuant to which, among other things, the Company will merge with and into a wholly-owned subsidiary of Rafael (the “Merger”). The Merger is subject to the satisfaction or waiver of several conditions set forth in the Merger Agreement and the approval of the Company’s and Rafael’s respective stockholders.

 

The descriptions of the Agreement and the Note are qualified in their entirety by reference to the actual terms thereof contained in the Agreement and the Note which are being filed as Exhibits 10.1 and 10.2, respectively, to this Current Report on Form 8-K, and such terms are incorporated herein by reference.

 

 

The information contained in Item 1.01 above is hereby incorporated by reference into this Item 2.03.

 

 

(d) Exhibits

 

 

+Filed herewith.

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.